MAM
MRSN

Martingale Asset Management’s Mersana Therapeutics MRSN Stock Holding History

Martingale Asset Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-485
Closed -$39.9K – 826
2023
Q2 		$39.9K Buy
485
+1
+0.2% +$146 ﹤0.01% 794
2023
Q1 		$49.8K Hold
484
– – ﹤0.01% 814
2022
Q4 		$71K Hold
484
– – ﹤0.01% 819
2022
Q3 		$82K Hold
484
– – ﹤0.01% 810
2022
Q2 		$56K Buy
484
+2
+0.4% +$188 ﹤0.01% 837
2022
Q1 		$49K Hold
482
– – ﹤0.01% 798
2021
Q4 		$75K Buy
+482
New +$93.8K ﹤0.01% 811

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Martingale Asset Management's MRSN Position: Q3 2023 in Review

Martingale Asset Management sold out of Mersana Therapeutics (MRSN) in Q3 2023, closing a stake of 485 shares — an estimated $39.9K sold.

Martingale Asset Management first reported a position in MRSN in Q4 2021 and held it in 7 quarters. The position peaked at $82K in Q3 2022. 128 funds tracked by Wall St. Rank hold MRSN as of Q3 2023.

  • Martingale Asset Management reported no remaining Mersana Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Martingale Asset Management sold 485 Mersana Therapeutics shares in Q3 2023, an estimated $39.9K.
  • Martingale Asset Management first reported a position in Mersana Therapeutics in Q4 2021 and held it in 7 quarters.
  • Martingale Asset Management's Mersana Therapeutics position peaked at $82K in Q3 2022.
  • 128 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2023.

Based on Martingale Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.